HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

YF-452

an angiogenesis inhibitor

Also Known As:

N-(N-pyrrolidylacetyl)-9-(4-bromobenzyl)-1,3,4,9-tetrahydro-beta-carboline

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Carbolines: 283
      - YF-452: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Carbolines: 283
        YF-452: 1
  - 3-Ring Heterocyclic Compounds
    - Carbolines: 283
      - YF-452: 1

Experts

1.	Chen, Yihua: 1 article (02/2017)
2.	Cong, Xiaonan: 1 article (02/2017)
3.	Gao, Dan: 1 article (02/2017)
4.	He, Yuan: 1 article (02/2017)
5.	Lan, Liping: 1 article (02/2017)
6.	Liu, Mingyao: 1 article (02/2017)
7.	Liu, Yongrui: 1 article (02/2017)
8.	Peng, Shihong: 1 article (02/2017)
9.	Wang, Jinhua: 1 article (02/2017)
10.	Wang, Weifang: 1 article (02/2017)

Related Diseases

1.

Neoplasms (Cancer)

02/01/2017 - "Moreover, YF-452 remarkably suppressed tumor growth in xenografts mice model. "
02/01/2017 - "These results indicate that YF-452 inhibits angiogenesis and may be a potential antiangiogenic drug candidate for cancer therapy."
02/01/2017 - "A novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling."

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)

Related Therapies and Procedures

1.	Therapeutics